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Cardiac Complications
Vascular Complications
Pathogenesis of COVID-19 Cardiovascular Disease and Effects The COVID-19 Patient
Conclusion
VTE
Concomitant venous and arterial 
thrombotic events
Coagulopathy
~31% of patients with COVID-19 in the ICU had 
thrombotic complications despite thromboprophylaxis. 
These patients exhibited prolonged PT (prothrombin 
time) and aPTT (activated partial thromboplastin time) 
time (3).
Several studies showed the presence of venous and 
arterial thrombosis in a high percentage of COVID-19 
patients, with suggestive lab values including elevated 
D- dimer and elevated c-reactive protein (4,5)
It is very important to screen high risk COVID-19 
patients that present with comorbidities especially 
hypertension for the potential of stroke. (6)
Studies have shown that important markers in high risk 
patients that may indicate stroke include:
Elevated D-dimer, cardiac troponin T, prothrombin time, 
and c-reactive protein (7).
Some COVID-19 patients present with a term known as 
COVID-19 associated coagulopathy (CAC), similar to DIC 
(disseminated intravascular coagulation).
CAC differs from DIC in that it has: 
elevated fibrinogen levels, elevated c-reactive protein, 




Similar to COVID-19, myocarditis is often 
preceded by flu-like and gastrointestinal 
symptoms (10)
46% of patients infected with COVID-19 with 
no known underlying cardiac disease had 
abnormal echocardiography findings (11))
Elevated troponin levels in COVID-19 patients 
were associated with elevated levels of CRP 
and NT-proBNP, linking myocardial injury to 
severity of inflammation,, and were also 
associated with a more severe disease course 
and worse prognosis (12-15)
Heart Failure
Heart failure related to ventricular 
dysfunction, myocarditis, acute coronary 
syndrome, arrythmia, pulmonary 
hypertension, ARDS, and cardiomyopathy 
occurs in up to 23% of COVID-19 patients 
(16,17).
- Patients with later confirmed COVID-19 may initially present to the doctor because of 
cardiovascular symptoms such as heart palpitations and chest tightness (30,31)
- Patients may also present with elevated cardiac biomarkers, myopericarditis, angina, 
chest pressure, ST-elevation, and systolic dysfunction without any signs or symptoms 
of infection such as fever, cough, dyspnea, or respiratory involvement (32-34)
- Atrial fibrillation, ventricular dysfunction, and myocarditis are sequelae seen in COVID-
19 patients despite  no evidence of prior CVD, CAD, HF, cancer, hypertension, or 
smoking
Does the risk of cardiovascular disease persist after COVID-19 infection?
- 10-year follow-up study showed an increased risk of cardiovascular disease and cardiac 
complications in pneumonia patients
- COVID-19 is primarily a respiratory illness and  is likely to cause similar, long-term 
outcomes (35)
- COVID-19-recovered patients, 2-3 months after diagnosis, showed cardiac MRI 
abnormalities in 78% and myocardial inflammation in 60% (36)
Six proposed mechanisms:
1. Angiotensin converting enzyme (ACE-2) receptor-dependent 
myocardial infection causing direct cardiac damage. (1)
2. Hypoxia-induced injury due to oxidative stress, acidosis, and 
mitochondrial damage. (1)
3. Inflammation resulting in vessel hyperpermeability and angiospasm, 
causing damage to the heart’s microvasculature. (1)
4. Systemic inflammatory reaction and cytosine storm mediating damage 
(1)
5. Vessel occlusion due to coagulopathy, thrombosis, embolus, plaque 
instability, or plaque rupture from system inflammatory response. (1)
6. Stress-induced cardiomyopathy and cardiac injury due to increases in 
catecholamines from a stress response in a patient. (1)
Acute Coronary Syndrome
Arrhythmias 
Increased thrombotic event risk can cause increased 
ACS risk in COVID-19 positive patients. (24) 
Myocardial injury with ST-segment elevation has 
been observed in positive patients in addition to 
reduced left ventricular ejection fraction and Brugada 
pattern have also been observed (25, 26-29)
16.7% of COVID-19 patients were seen with arrhythmias 
with 44.4% prevalence in those who were admitted to the 
ICU (18, 19)
Arrhythmias could be due to myocarditis, myocardial 
ischemia, infection-induced hypoxia, fever, metabolic 
disarray, hormonal dysregulation, medication (ex. 
azithromycin and hydroxychloroquine COVID-19 
treatments), or inflammation. (20, 21, 22, 23)
Stroke
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Acute cardiac injury is a common cardiovascular complication of Covid19 and little is currently 
known about the long term implications of the complications and manifestations. Vascular 
complications show a hypercoagulable state which indicates potential for thromboembolism. By 
monitoring for both cardiac and vascular complications after hospitalization and administering 
anti-platelet and anti-coagulation therapies we have seen prevention of complications such as VTE. 
Developing a CV screening protocol for Covid-19 patients and recovered patients is crucial in 
monitoring and further research.
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